^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LYL845
i
Other names: LYL845, LYL-845, LYL 845
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lyell Immunopharma
Drug class:
Immunostimulant
Related drugs:
5ms
A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
P1, N=108, Recruiting, Lyell Immunopharma, Inc.
Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF mutation
|
LYL845
over1year
A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
P1, N=108, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF mutation
|
LYL845
over1year
A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
P1, N=108, Not yet recruiting, Lyell Immunopharma, Inc.
New P1 trial • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
MSI-H/dMMR • BRAF mutation
|
LYL845
Share via
